In an interview with Redeye, CEO Sofia Heigis discusses the significance of the data from the INSULA study in glioblastoma and how the SEK 100 million raised through the directed share issue will be used.
The interview is in Swedish.
In an interview with Redeye, CEO Sofia Heigis discusses the significance of the data from the INSULA study in glioblastoma and how the SEK 100 million raised through the directed share issue will be used.
The interview is in Swedish.
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care
Learn more about the company Oncopeptides and the work we do to redefine cancer care